Efficacy and Safety of Everolimus in Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Lung: A Subgroup Analysis of the Phase 3 RADIANT-4 Study

被引：0

作者：

Fazio, N. ^{[1
]}

Buzzoni, R. ^{[2
]}

Delle Fave, G. ^{[3
]}

Tesselaar, M. ^{[4
]}

Wolin, E. ^{[5
]}

Van Cutsem, E. ^{[6
,7
]}

Tomassetti, P. ^{[8
]}

Strosberg, J. ^{[9
]}

Voi, M. ^{[10
]}

Bubuteishvili-Pacaud, L. ^{[11
]}

Ridolfi, A. ^{[12
]}

Singh, S. ^{[13
]}

Pavel, M. ^{[14
]}

Kulke, M. ^{[15
]}

Yao, J. ^{[16
]}

机构：

[1] Ist Europeo Oncol, IRCCS, Milan, Italy

[2] Fdn IRCCS, Ist Nazl Tumori, Milan, Italy

[3] Univ Roma La Sapienza, Azienda Osped St Andrea, Rome, Italy

[4] Netherlands Canc Inst, Amsterdam, Netherlands

[5] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA

[6] Univ Hosp Gasthuisberg Leuven, Leuven, Belgium

[7] Katholieke Univ Leuven, Leuven, Belgium

[8] Univ Bologna, S Orsola Malpighi Hosp, Dept Med & Surg Sci, Bologna, Italy

[9] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[10] Novartis Pharmaceut, E Hanover, NJ USA

[11] Novartis Pharma AG, Basel, Switzerland

[12] Novartis Pharma SAS, Rueil Malmaison, France

[13] Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada

[14] Charite, Virchow Klinikum, Berlin, Germany

[15] Dana Farber Canc Inst, Boston, MA 02115 USA

[16] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

关键词：

PFS; Everolimus; Lung carcinoid;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：104 / 104

页数：1